Full Breakdown
HHS Grants Temporary Enforcement Discretion for Six Unapproved Peptides
By Drooid · · How we work
In this breakdown
01
Core Policy Announcement
On October 28, the U.S. Department of Health and Human Services (HHS) released an “enforcement discretion” policy that permits licensed pharmacies and physicians to compound six peptide ingredients that have not received FDA approval: BPC-157, TB-500 (the “Wolverine stack”), epitalon, KPV, MOTS-c, and Semax. Compounders may proceed without fear of FDA enforcement if they meet HHS-specified requirements for ingredient quality, manufacturing standards, safety reporting, labeling, and patient-specific prescriptions. The policy is interim while the agency evaluates a formal rule change.
02
Background & Context
Peptides—short chains of amino acids—have surged in popularity, driven by wellness influencers who promote them for anti-aging, muscle recovery, wound healing, insomnia, obesity, osteoporosis, migraines, and chronic pain. Because they are not FDA-approved, most are sold as “research-use-only” products, a classification that avoids labeling for human consumption. An FDA advisory panel voted in July to recommend that compounding pharmacies be allowed to manufacture the six peptides, despite staff recommendations against it. HHS cited the policy as a means to discourage the import of foreign-manufactured research-use-only peptides that may pose safety risks and to improve patient access.
Visual evidence
Images from the story
03
Data & Market Outlook
Industry analysts estimate that legitimizing peptide compounding could expand the peptide market to a value of $2 billion to $3 billion. Telehealth firms such as Hims & Hers Health have indicated plans to roll out peptide offerings once federal clearance is secured.
04
Official Statements & Responses
05
Verbatim Quotes
- “Under President Trump’s leadership, HHS is working to put prevention and patient safety at the center of health care—and that includes confronting the risks of black-market peptides,” — Emily Hilliard, HHS spokesperson
06
Conflicting Reports & Gaps
Sources differ on the internal FDA stance: an advisory panel voted to recommend allowing the six peptides in compounding, while FDA staff had recommended against the change. The policy does not constitute FDA approval of the peptides or of compounded medicines made from them, and HHS has not detailed how it will monitor safety signals after implementation.